PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
A versatile spicy peanut chutney that can be used as a spread, marinade, dip or condiment. Kit's Peanut Chutney is homemade using natural ingredients, as well as being vegan nad gluten-free. The company is seeking investment mass produce their products and increase the number of stockists that list their range.
Currently, the products are stocked by nine independent retailers and new outlets are being added every day. To date, more than 600 jars have been sold. By increasing their production, they aim to lower the cost of their products whilst yielding a 73% gross profit margin per jar sold. Wholesaling will yield a gross profit margin of 44% per jar.
days to go:
Expired
investment:
£102,510
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Rubies in the Rubble is an independent business which makes and sells an award-winning range of condiments prepared with delicious ingredients that would otherwise go to waste. The company offers classic ketchup & plant-based mayo, and it has signed up to supply the products to Sainsbury's, Marriott Group and many more. The company has witnessed growth in sales, and is planning to launch the ketchup in retail during the latter half of 2019. With the proceeds, the company will expand its sales and marketing team.
days to go:
Expired
investment:
£2,029,709
Resolve Divorce are an online platform, founded by an experienced legal team and aiming to automate the divorce process without solicitors, at a fixed fee. In the UK there are over 100,000 divorces a year and the market is estimated to be worth over £3bn a year.
days to go:
Expired
investment:
£9,540
Redwell Brewing is a small batch independent brewery offering an entire range which is audited gluten-free and certified vegan. Well known for its handmade beer, the brewery’s booming taproom and events space which opened in 2018 on a shoestring budget of £200 is also a well-loved destination with sales of £30,000 in December 2018 alone. The brewery has partnered with several retailers and wholesalers, including creating an own-label craft beer for ALDI. With focus on flavours and community, Redwell Brewing is constantly innovating and winning awards, such as three GOLDs in the World Beer Awards. With the proceeds, it's planning to expand its facilities and its range into on and off trading outlets beyond the UK.
days to go:
Expired
investment:
£75,650
Felcana is a patented Eco-system of connected devices: Helix, Home Hub, Micro-Location Beacons and the Felcana application which work together to monitor the pet's (cat or dogs) well-being. This Digital Pet Health Platform tracks pet's behaviour and provides the vet, rich data leading to faster diagnosis and faster treatment. Felcana has been developed by a world-class team of vets and engineers and, it has been designed and tested by using the latest materials, designs, and techniques. Felcana has won the Design Spark Award in 2017. It is making unique partnerships with leading pet industries and the UK's largest pet health plan provider, the world's top-ranked vet school and The Royal Veterinary College. The new investment will enable it to grow consumer reach and accelerate its sales.
days to go:
Expired
investment:
£343,926
